You might know you need to conduct drug metabolism and pharmacokinetic (DMPK) analysis, but which tests are right for your project? And are you doing them at the right time? When building your preclinical strategy, these questions matter—and that’s true now more than ever, as new drug classes and targets emerge.
September 30, 2020
- The Technology Behind Spectral Flow Cytometry
- Outrunning Resistance: Why Preclinical Insight Is the Key to Durable Oncology Therapies
- New Cytometric Horizons using Spectral Flow Cytometry
- Publication of CLSI H62 Validation of Assays Performed by Flow Cytometry
- Using Flow Cytometry to Immunophenotype Dendritic Cells: Master Regulators of the Immune System
The Technology Behind Spectral Flow Cytometry
By Jayne Schaubhut, Lab Supervisor
Outrunning Resistance: Why Preclinical Insight Is the Key to Durable Oncology Therapies
Therapeutic resistance remains one of the most significant barriers to durable responses in oncology. Whether primary or acquired, resistance ...
New Cytometric Horizons using Spectral Flow Cytometry
By Maria Hansen
Get Started
Contact Us Today!
If you’re looking for an expert team to guide your trial with efficiency in mind, we can help. As the creators of the Dynamic Trial, TD2 provides start-to-finish support with trial strategy, design and execution for faster go-to-market potential.
